Bausch + Lomb (BLCO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
20 May, 2026Opening remarks and agenda
Meeting called to order by the Chairman and CEO, with board, management, and auditor representatives present.
Notice of meeting and proxy statement distributed to shareholders of record; quorum confirmed.
Shareholder proposals
Four proposals presented: election of directors, advisory vote on executive compensation, auditor appointment, and one withdrawn proposal.
Board recommended voting for all active proposals; no other director nominations received.
Shareholders could submit questions via webcast, limited to proposal topics.
Corporate governance
Election of directors to serve until the 2027 annual meeting or until successors are appointed.
Appointment of PricewaterhouseCoopers as auditor until the 2027 annual meeting, with board authorized to set remuneration.
Latest events from Bausch + Lomb
- Operational excellence and breakthrough innovation drive growth and margin expansion through 2028.BLCO
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Bioactive and myopia control lenses target 2028–2029 launches, with peak sales up to $500M.BLCO
R&D Day 20262 Jun 2026 - Q1 2026 revenue up 9%, adjusted EBITDA up 59%, and full-year guidance raised.BLCO
Q1 202629 Apr 2026 - 5–7% revenue CAGR, ~$7B pipeline peak sales, and margin expansion driven by innovation and discipline.BLCO
44th Annual J.P. Morgan Healthcare Conference20 Apr 2026 - Proxy covers director elections, pay, incentive plan, auditor, and major ESG progress.BLCO
Proxy filing10 Apr 2026 - BL1107 and ELIOS show strong clinical data and market potential, with U.S. launches in 2H26.BLCO
Status update23 Mar 2026 - Record Q4 and full year results drive strong 2026 growth outlook and margin expansion.BLCO
Q4 202518 Feb 2026 - Strong Q1 growth, robust innovation pipeline, and tariff impacts fully offset for 2025.BLCO
Jefferies Global Healthcare Conference 20253 Feb 2026 - Revenue up 20% constant currency; guidance raised despite higher net loss and costs.BLCO
Q2 20242 Feb 2026